Haleon plc (HLN) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Haleon plc stock $8.57, price $8.66, that is 1.0% below the price, quality 71 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.
How to read this chart
51‑month range $5.26 – $11.12 · fair‑value band $5.35 – $12.51 · the $8.66 price screens above the $8.57 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 30, 2026.
Follow Haleon in your weekly email
Every Wednesday you see whether Haleon is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Show moreShow less
The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues.
Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Stock analysis
Haleon plc (HLN) currently trades at $8.66, while our model-based Fair Value estimate is $8.57, so the stock looks roughly fairly valued today (gap 1.1%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $9.58 per share, and 6 of the 22 models we run sit above the $8.66 price.
Bear case: the Dividend Discount group reads lowest at $2.27, and 16 of the 22 models stay below the price. Data coverage for this calculation is high.
Scenario range: $5.35 (bear) to $12.51 (bull), the price of $8.66 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Haleon plc reported revenue of £11.0B in FY2025 versus £9.5B in FY2021, a compound +3.7%/yr. Reported net income was £1.6B in FY2025, compounding +4.1%/yr from FY2021.
Key figures
Market cap $44.0B Large · P/E ratio 17.7 · P/S ratio 2.61 · EPS (TTM) $0.4900 · Dividend yield 0.8% · Net margin 14.8% · Return on equity 10.1% · Return on assets (EBIT) 5.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (medium confidence).
What moves the price
The share trades about 22% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −1%, HLN screens cheaper than that median.
Fair Value models
Bear$5.35Fair Value $8.57Bull$12.51
Price $8.66 · Downside -1.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.3496 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +9.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.1%
Dividend (yield on the price)0.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 22%
⚠ Rate on operating basis: 2025 sits 58% above its own trend.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in GBP, UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +1.1% a year for the price and +1.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Legacy brand distribution and cash conversion provide the main strength, while high leverage after the spin-off and average returns form the key weakness.
Main risk: Cheaper private-label offerings from retailers and rivals such as Kenvue might win shelf space and market share from Haleon's brands including Sensodyne and Advil, pressuring prices and margins in oral care and pain relief.
Bull case: By leveraging its brand strength and the Win as One plan to drive innovation and consumer loyalty, Haleon could defend premium pricing and capture additional share from private labels in therapeutic categories.
Bear case: If private labels and named rivals continue to improve perceived quality and secure better retail positions, Haleon might face ongoing margin pressure and volume losses across its core consumer health portfolio.
Haleon is adding a Chief Growth Officer and a Chief Transformation Officer while moving to a six-unit operating model to boost agility and execution under its Win as One plan. The changes target faster scalable growth yet arrive against a backdrop of soft sales trends. Will the new structure deliver clearer momentum or risk further distraction from day-to-day performance?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 550 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside−1.0% · Above median
Profitability
Return on equity (12 months)10.1% · Above median
Return on assets5.0% · Above median
Net margin (12 months)14.6% · Above median
Operating margin (12 months)23.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)2.2% · Below median
Dividend yield (12 months)0.8% · Below median
Balance sheet
Debt / equity0.47× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)17.7× · Cheaper than median
P/B2.00× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Haleon plc Fair Value". https://www.fairvalue-calculator.com/stock/HLN
Frequently asked questions
Is Haleon plc (HLN) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of $8.57 versus a price of $8.66, about 1% lower (fairly valued).
What is the fair value of HLN?
Our model-based fair value for Haleon plc is $8.57 (as of Oct 30, 2026), built from audited fundamentals. The current price: $8.66.
What is the quality score of HLN?
Haleon plc has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Haleon plc (HLN)?
Our model-based price target is the fair value of $8.57 (as of Oct 30, 2026) from 22 valuation models. Cautious scenario $5.35, optimistic scenario $12.51. It is a calculation from audited fundamentals, not an analyst target.
What is the Haleon plc stock forecast for 2026?
Our models put fair value at $8.57, about 1% lower versus a price of $8.66 (fairly valued). Cautious scenario $5.35, optimistic scenario $12.51. The calculation is refreshed regularly with new filings.
What is the revenue of Haleon plc (HLN)?
Haleon plc reported trailing-twelve-month revenue of about £11.2B (latest available figure, as of Oct 30, 2026).
Does Haleon plc pay a dividend?
Haleon plc currently shows a dividend yield of 0.84% relative to its recent price (as of Oct 30, 2026).
What growth is priced into Haleon plc (HLN)?
For today's price to be fair in a discounted-cash-flow model, Haleon plc would have to grow free cash flow by +3.4 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.2 % per year. As of Oct 30, 2026.
What discount rate (WACC) does the fair value of HLN use?
Our models discount Haleon plc at 8.1 %: a base by market capitalisation (large), damped by beta 0.28, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Haleon plc that is +3.4 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Haleon plc (HLN) delivered so far?
Over the past 5 years revenue at Haleon plc grew +2.2 % a year. The price currently implies +3.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Haleon plc (HLN) growing?
The median revenue growth in the sector is +6.4 % a year. That is the yardstick for the growth priced into Haleon plc (+3.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Haleon plc (HLN)?
The free-cash-flow yield on the price is 6.85 %: that much free cash flow Haleon plc produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Haleon plc (HLN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Haleon plc it is $8.57 per share (as of Oct 30, 2026), against a price of $8.66. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Haleon plc stock overvalued or undervalued in 2026?
As of Oct 30, 2026, HLN trades above its calculated fair value: price $8.66, fair value $8.57, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HLN?
No. The price is what the market pays today ($8.66); the fair value is what the company's own numbers justify ($8.57). For Haleon plc the two are $0.0900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Haleon plc worth?
The market values Haleon plc at about $44.0B (market capitalisation, as of Oct 30, 2026). Per share that is $8.66; our models calculate a fair value of $8.57 per share.
What do the bullish and bearish scenarios say about HLN?
Our models span a range for Haleon plc: cautious scenario $5.35, base $8.57, optimistic $12.51 per share (as of Oct 30, 2026, price $8.66). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HLN?
Haleon plc trades at a price-to-earnings ratio of 17.7 (as of Oct 30, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $8.57 is built from several models across several years. Other multiples: PEG 2.3, P/B 2.0, P/S 2.9, EV/EBITDA 13.8.
What is the PEG ratio of HLN?
The PEG ratio of Haleon plc is 2.29 (P/E divided by earnings growth, as of Oct 30, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Haleon plc (HLN)?
Balance-sheet figures for Haleon plc (as of Oct 30, 2026): return on equity 10.1%, debt of 0.47 per unit of equity. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is HLN from its 52-week high?
Haleon plc trades at $8.66, about 22% below its 52-week high of $11.05 and 1% above the low of $8.57 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $8.57 is for.
Which stocks are comparable to Haleon plc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Jiangsu Hengrui Pharmaceuticals Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Haleon plc stock attractive at the current price?
The data as of Oct 30, 2026: price $8.66, calculated fair value $8.57 (−1%), Quality Score 71/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HLN calculated?
We run Haleon plc through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.57, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Haleon plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Haleon plc (HLN)?
The closing price on Oct 30, 2026 was $8.66. Our model-based fair value is $8.57, about 1% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Haleon plc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($5.35 to $12.51) leaves room in how you read the outcome.
Key figures of Haleon plc
How large is the market capitalisation of Haleon plc (HLN)?
The market capitalisation of Haleon plc is $44.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Haleon plc (HLN)?
The price-to-sales ratio of Haleon plc is 2.61 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Haleon plc (HLN)?
Earnings per share at Haleon plc are $0.4900 (price ÷ EPS = P/E 17.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Haleon plc (HLN)?
The dividend yield of Haleon plc is 0.8% (payout 14.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Haleon plc (HLN)?
The net margin of Haleon plc is 14.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Haleon plc (HLN)?
The return on equity (ROE) of Haleon plc is 10.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Haleon plc (HLN)?
On an EBIT basis the return on assets of Haleon plc is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Haleon plc (HLN)?
The operating margin of Haleon plc is 23.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Haleon plc (HLN)?
Revenue at Haleon plc is growing +2.2% versus a year earlier (3y avg +0.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Haleon plc (HLN)?
Earnings per share at Haleon plc are growing −4.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Haleon plc (HLN) carry?
The net debt of Haleon plc is £7.3B (fiscal year 2025, ≈ 3.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Haleon plc in the live analysis
One click puts Haleon plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Oct 30, 2026